Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the H.C. Wainwright 21st Annual Global Investment Conference being held September 8-10, 2019 in New York.
Category: News
Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin
Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need
The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections
Once-daily NUZYRA is non-inferior to twice-daily oral linezolid for the treatment of adults with ABSSSI, including MRSA; confirms efficacy and safety of oral-only formulation
VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
Demonstrated potent activity against carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa
Venatorx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
Venatorx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections Demonstrated potent activity against carbapenem-resistant Enterobacteriaceae andcarbapenem-resistant Pseudomonas aeruginosa VNRX-5133 may provide a therapeutic option for these emerging pathogens, which are classified as urgent public health threats by the Centers for Disease Control and Prevention Malvern, PA, August...
Nabriva Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schroeder will provide a company overview and business update at the 17th Annual...
Paratek Pharmaceuticals to Present at Robert W. Baird’s 2019 Global Healthcare Conference
BOSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at Baird’s 2019 Global Healthcare Conference on Wednesday, September 4 at 3:10 p.m. ET at the InterContinental New York Barclay in New York.
VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio
MALVERN, Pa.–(BUSINESS WIRE)–VenatoRx Pharmaceuticals today announced the addition of pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta to its development team. These appointments come as the Company continues to advance its portfolio of antibacterial and antiviral assets through their respective pre-clinical and clinical milestones.
Cidara Therapeutics to Present Data from its Cloudbreak Antiviral Program at the Options X for the Control of Influenza Conference
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak® antiviral program have been accepted for presentation at the Options X for the Control of Influenza conference taking place August 28-September 1 in Singapore.
Venatorx Pharmaceuticals Expands Development Team as it Advances its Antibacterial and Antiviral Portfolio
Venatorx Pharmaceuticals Expands Development Team as it Advances its Antibacterial and Antiviral Portfolio Key Hires in Quality Assurance, Medical Sciences and Regulatory Affairs Malvern, PA, August 21, 2019 – Venatorx Pharmaceuticals today announced the addition of pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta to its development team. These appointments come...